Annie Luetkemeyer, MD, professor of infectious diseases at UCSF, is an expert on the treatment of viral infections. Robert Wachter, MD, MHM, chair of the UCSF Department of Medicine, interviewed her about the evidence behind potential treatments for COVID-19 (including chloroquine/hydroxychloroquine, remdesivir, and others), as well as how to assess new and existing drugs in a pandemic.
Clinical
Treatment options for COVID-19: Dr. Annie Luetkemeyer
Clinical
-
U.K. variant spreading in the U.S. as COVID mutations raise stakes -
Brazilian researchers tracking reinfection by new virus variant -
President Biden to up states’ vaccine supplies, targets more doses -
-
COVID-19 variants may prompt additional Moderna vaccine -
Even patients with cancer in remission at risk for severe COVID-19 -
More than one-third of COVID-19 infections are asymptomatic: Review -
Vaccines may not be as effective against variants -
ColCORONA: Colchicine reduces complications in outpatient COVID-19 -
Full-dose anticoagulation reduces need for life support in COVID-19
Quality
Public Policy
-
President Biden kicks off health agenda with COVID actions, WHO outreach -
-
Feds to states: Give COVID-19 vaccine to 65+ and those with comorbidities -
COVID-related harm to HCWs must be tracked more rigorously: NAS panel -
Quick Byte: Global health before COVID-19
Practice Management
-
-
COVID-19 drives physician burnout for some specialties -
-
-
-
Hospital volumes start to fall again, even as COVID-19 soars -
-
-
COVID-related harm to HCWs must be tracked more rigorously: NAS panel -
From the Society
Video
-
Critical care and COVID-19: Dr. Matt Aldrich -
Treatment options for COVID-19: Dr. Annie Luetkemeyer -
Managing the COVID-19 isolation floor at UCSF Medical Center -
-
